Physicians

Director, Division of Gynecologic Oncology

Department / Division
Obstetrics/Gynecology / Gynecology Oncology

Address
DUMC 3079
Durham, NC 27710

Appointment Telephone
919-684-3765

Office Telephone
919-684-3765

Fax Telephone
919-684-8719

Training

• MD, Case Western Reserve University School of Medicine (Ohio), 1980

Residency

• OB-GYN, Case Western Reserve University (Ohio), 1980-1984

Fellowship

• Gynecologic Oncology, Sloan-Kettering Cancer Center (New York), 1985-1987

Clinical Interests
Gynecologic malignancies, premalignant diseases of the cervix and vagina, radical pelvic surgery, chemotherapy, radiation therapy, reconstructive pelvic surgery, laser surgery, complicated gynecologic surgery, hereditary ovarian and endometrial cancer, minimally invasive laparoscopic surgery

Research Interests
Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the F. Bayard Carter Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Baba, T; Convery, PA; Matsumura, N; Whitaker, RS; Kondoh, E; Perry, T; Huang, Z; Bentley, RC; Mori, S; Fujii, S; Marks, JR; Berchuck, A; Murphy, SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009;28:209-218. (2009) Abstract

Berchuck, A; Iversen, ES; Luo, J; Clarke, JP; Horne, H; Levine, DA; Boyd, J; Alonso, MA; Secord, AA; Bernardini, MQ; Barnett, JC; Boren, T; Murphy, SK; Dressman, HK; Marks, JR; Lancaster, JM. Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome. Clinical Cancer Research. 2009;15:2448-2455. (2009) Abstract

Schildkraut, JM; Goode, EL; Clyde, MA; Iversen, ES; Moorman, PG; Berchuck, A; Marks, JR; Lissowska, J; Brinton, L; Peplonska, B; Cunningham, JM; Vierkant, RA; Rider, DN; Chenevix-Trench, G; Webb, PM; Beesley, J; Chen, X; Phelan, C; Sutphen, R; Sellers, TA; Pearce, L; Wu, AH; Van Den Berg, D; Conti, D; Elund, CK; Anderson, R; Goodman, MT; Lurie, G; Carney, ME; Thompson, PJ; Gayther, SA; Ramus, SJ; Jacobs, I; Krüger Kjaer, S; Hogdall, E; Blaakaer, J; Hogdall, C; Easton, DF; Song, H; Pharoah, PD; Whittemore, AS; McGuire, V; Quaye, L; Anton-Culver, H; Ziogas, A; Terry, KL; Cramer, DW; Hankinson, SE; Tworoger, SS; Calingaert, B; Chanock, S; Sherman, M; Garcia-Closas, M; Australian Ovarian Cancer Study Group. Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Research. 2009;69:2349-2357. (2009) Abstract

Berchuck, A. Scientific innovation--pathway to progress in women's cancer. Gynecologic Oncology. 2008;109:316-322. (2008) Abstract

Havrilesky, LJ; Whitehead, CM; Rubatt, JM; Cheek, RL; Groelke, J; He, Q; Malinowski, DP; Fischer, TJ; Berchuck, A. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology. 2008;110:374-382. (2008) Abstract

Palmieri, RT; Wilson, MA; Iversen, ES; Clyde, MA; Calingaert, B; Moorman, PG; Poole, C; Anderson, AR; Anderson, S; Anton-Culver, H; Beesley, J; Hogdall, E; Brewster, W; Carney, ME; Chen, X; Chenevix-Trench, G; Chang-Claude, J; Cunningham, JM; Dicioccio, RA; Doherty, JA; Easton, DF; Edlund, CK; Gayther, SA; Gentry-Maharaj, A; Goode, EL; Goodman, MT; Kjaer, SK; Hogdall, CK; Hopkins, MP; Jenison, EL; Blaakaer, J; Lurie, G; McGuire, V; Menon, U; Moysich, KB; Ness, RB; Pearce, CL; Pharoah, PD; Pike, MC; Ramus, SJ; Rossing, MA; Song, H; Terada, KY; Vandenberg, D; Vierkant, RA; Wang-Gohrke, S; Webb, PM; Whittemore, AS; Wu, AH; Ziogas, A; Berchuck, A; Schildkraut, JM; Ovarian Cancer Association Consortium, ; Australian Cancer Study (Ovarian Cancer Group), ; Australian Ovarian Cancer Study Group. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3567-3572. (2008) Abstract

Pearce, CL; Wu, AH; Gayther, SA; Bale, AE; Australian Cancer Study (Ovarian Cancer) and Australian Cancer Study Group, ; Beck, PA; Beesley, J; Chanock, S; Cramer, DW; DiCioccio, R; Edwards, R; Fredericksen, ZS; Garcia-Closas, M; Goode, EL; Green, AC; Hartmann, LC; Hogdall, E; Kjaer, SK; Lissowska, J; McGuire, V; Modugno, F; Moysich, K; Ness, RB; Ramus, SJ; Risch, HA; Sellers, TA; Song, H; Stram, DO; Terry, KL; Webb, PM; Whiteman, DC; Whittemore, AS; Zheng, W; Pharoah, PD; Chenevix-Trench, G; Pike, MC; Schildkraut, J; Berchuck, A; Ovarian Cancer Association Consortium. Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. British Journal of Cancer. 2008;98:282-288. (2008) Abstract

Schildkraut, JM; Moorman, PG; Bland, AE; Halabi, S; Calingaert, B; Whitaker, R; Lee, PS; Elkins-Williams, T; Bentley, RC; Marks, JR; Berchuck, A. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:585-593. (2008) Abstract

Dressman, HK; Berchuck, A; Chan, G; Zhai, J; Bild, A; Sayer, R; Cragun, J; Clarke, J; Whitaker, RS; Li, L; Gray, J; Marks, J; Ginsburg, GS; Potti, A; West, M; Nevins, JR; Lancaster, JM. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. Journal of Clinical Oncology. 2007;25:517-525. (2007) Abstract

Spillman, MA; Lacy, J; Murphy, SK; Whitaker, RS; Grace, L; Teaberry, V; Marks, JR; Berchuck, A. Regulation of the metastasis suppressor gene MKK4 in ovarian cancer. Gynecologic Oncology. 2007;105:312-320. (2007) Abstract

Bild, AH; Yao, G; Chang, JT; Wang, Q; Potti, A; Chasse, D; Joshi, MB; Harpole, D; Lancaster, JM; Berchuck, A; Olson, JA; Marks, JR; Dressman, HK; West, M; Nevins, JR. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-357. (2006) Abstract

Guillem, JG; Wood, WC; Moley, JF; Berchuck, A; Karlan, BY; Mutch, DG; Gagel, RF; Weitzel, J; Morrow, M; Weber, BL; Giardiello, F; Rodriguez-Bigas, MA; Church, J; Gruber, S; Offit, K; ASCO, ; SSO. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Journal of Clinical Oncology. 2006;24:4642-4660. (2006) Abstract

Jewell, E; Secord, AA; Brotherton, T; Berchuck, A. Use of trastuzumab in the treatment of metastatic endometrial cancer. International Journal of Gynecological Cancer. 2006;16:1370-1373. (2006) Abstract

Potti, A; Dressman, HK; Bild, A; Riedel, RF; Chan, G; Sayer, R; Cragun, J; Cottrill, H; Kelley, MJ; Petersen, R; Harpole, D; Marks, J; Berchuck, A; Ginsburg, GS; Febbo, P; Lancaster, J; Nevins, JR. Genomic signatures to guide the use of chemotherapeutics. Nature Medicine. 2006;12:1294-1300. (2006) Abstract

Schildkraut, JM; Moorman, PG; Halabi, S; Calingaert, B; Marks, JR; Berchuck, A. Analgesic drug use and risk of ovarian cancer. Epidemiology. 2006;17:104-107. (2006) Abstract

Berchuck, A; Iversen, ES; Lancaster, JM; Pittman, J; Luo, J; Lee, P; Murphy, S; Dressman, HK; Febbo, PG; West, M; Nevins, JR; Marks, JR. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clinical Cancer Research. 2005;11:3686-3696. (2005) Abstract

Cragun, JM; Havrilesky, LJ; Calingaert, B; Synan, I; Secord, AA; Soper, JT; Clarke-Pearson, DL; Berchuck, A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. Journal of Clinical Oncology. 2005;23:3668-3675. (2005) Abstract

Spillman, MA; Schildkraut, JM; Halabi, S; Moorman, P; Calingaert, B; Bentley, RC; Marks, JR; Murphy, S; Berchuck, A. Transforming growth factor beta receptor I polyalanine repeat polymorphism does not increase ovarian cancer risk. Gynecologic Oncology. 2005;97:543-549. (2005) Abstract

Berchuck, A; Schildkraut, JM; Wenham, RM; Calingaert, B; Ali, S; Henriott, A; Halabi, S; Rodriguez, GC; Gertig, D; Purdie, DM; Kelemen, L; Spurdle, AB; Marks, J; Chenevix-Trench, G. Progesterone receptor promoter +331A polymorphism is associated with a reduced risk of endometrioid and clear cell ovarian cancers. Cancer Epidemiology, Biomarkers and Prevention. 2004;13:2141-2147. (2004) Abstract

Havrilesky, L; Darcy, KM; Hamdan, H; Priore, RL; Leon, J; Bell, J; Berchuck, A; Gynecologic Oncology Group Study. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology. 2003;21:3814-3825. (2003) Abstract